Skip to main content
. 2022 Nov 11;144(46):21304–21317. doi: 10.1021/jacs.2c09232

Figure 2.

Figure 2

(A) Viability (mitochondrial activity via MTS assay) of HDFn (left) and RAW 246.7 macrophages (center) after 24 h of incubation as a function of the concentration of PTGG30 or mPEG (5 kDa) for 24 h (n = 3); viability of RAW cells was also assessed after treatment with PTGG and PEG at concentration of 1 mg/mL for 24 or 48 h. Cells were also treated with 5% DMSO as positive control. (B) Uptake of FITC-labeled PTGG30 and mPEG into RAW 246.7 macrophages after 24 exposure (fluorescence measured in cell lysates, n = 3). (C) Complement activation by PTGG30 or mPEG as assessed through the production of two soluble markers, C3a (left) and C5a (right), in human serum. Zymosan and PBS were used, respectively, as the positive and negative control (n = 3). Statistical significance: one-way analysis of variance (ANOVA) with a Tukey’s means comparison; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.